Table 1 Characteristics of the population
|  | N = 228 |
|---|---|
Age | 60.0 (31–89) |
Tumor Size (mm) | 15.7 (+/- 2.8, min–max 8–20) |
Number of involved lymph nodes | Â |
No involved node | 160 (70%) |
1–2 involved node | 68 (30%) |
Multifocality | 84 (37%) |
Extensive DCIS | 94 (41%) |
Tumor grade (SBR) | Â |
Grade I | 96 (42%) |
Grade II | 132 (58%) |
ER expression (H-score) | 277 (+/- 66) |
ER-positive | 224 (98%) |
ER-negative | 4 (2%) |
PR expression (H-score) | 205 (+/- 112) |
PR-positive | 191 (84%) |
PR-negative | 37 (16%) |
Ki67 expression (H-score) | 13.2 (+/- 8.4) |
Ki67 < 15% | 144 (63%) |
Ki67 > 15% | 84 (37%) |
uPA level (ng/mg) | 2.65 (+/- 2.2) |
PAI1 level (ng/mg) | 11.79 (+/- 11.87) |
MMP-11 expression (H-score) | 59 (+/- 84) |
IH-MMP-11 < 50 | 138 (61%) |
IH-MMP-11 > 50 | 90 (39%) |
Surgery type | Â |
Lumpectomy | 167 (73%) |
Mastectomy | 61 (27%) |
Adjuvant therapy | Â |
Chemotherapy | 73 (32%) |
Radiation therapy | 197 (84%) |
Hormone therapy | 228 (100%) |